The impact of financing of screening tests on utilization and outcomes: The case of amniocentesis

Ity Shurtz, Amnon Brzezinski, Ayala Frumkin

Research output: Contribution to journalArticlepeer-review

4 Scopus citations

Abstract

We use a 1993 policy change in Israel's public healthcare system that lowered the eligibility age for amniocentesis to 35 to study the effects of financing of screening tests. Financing is found to have increased amniocentesis testing by about 35%. At ages above the eligibility threshold, utilization rates rose to roughly 33%, reflection nearly full takeup among prospective users of amniocentesis. Additionally, whereas below the age-35 threshold amniocentesis utilization rates increase with maternal age, this relation is muted above this age. Finally, no evidence is found that financing affects outcomes such as pregnancy terminations and births of children with Down syndrome. These results support the view that women above the eligibility threshold tend to refrain from acquiring inexpensive information about their degree of risk that absent the financing they would acquire, and instead, undergo the accurate and costly test regardless of additional information that noninvasive screening would provide.

Original languageEnglish
Pages (from-to)61-73
Number of pages13
JournalJournal of Health Economics
Volume48
DOIs
StatePublished - 1 Jul 2016
Externally publishedYes

Keywords

  • Behavior Health
  • Government Policy
  • Health Insurance
  • Public Health
  • Public and Private Health
  • Regulation

Fingerprint

Dive into the research topics of 'The impact of financing of screening tests on utilization and outcomes: The case of amniocentesis'. Together they form a unique fingerprint.

Cite this